NASDAQ:ALEC Alector (ALEC) Stock Forecast, Price & News $6.88 +0.85 (+14.10%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$6.28▼$6.9350-Day Range$5.20▼$8.7752-Week Range$4.98▼$10.07Volume1.11 million shsAverage Volume580,559 shsMarket Capitalization$576.75 millionP/E RatioN/ADividend YieldN/APrice Target$14.89 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Alector MarketRank™ ForecastAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside116.4% Upside$14.89 Price TargetShort InterestBearish9.85% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.42Based on 3 Articles This WeekInsider TradingSelling Shares$3.07 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.85) to ($2.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.48 out of 5 starsMedical Sector506th out of 968 stocksBiological Products, Except Diagnostic Industry74th out of 160 stocks 4.3 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.89, Alector has a forecasted upside of 116.4% from its current price of $6.88.Amount of Analyst CoverageAlector has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.85% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Alector has recently decreased by 3.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -0.92. Previous Next 3.0 News and Social Media Coverage News SentimentAlector has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alector this week, compared to 1 article on an average week.Search Interest10 people have searched for ALEC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows2 people have added Alector to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,067,340.00 in company stock.Percentage Held by Insiders14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.71% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to decrease in the coming year, from ($1.85) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alector (NASDAQ:ALEC) StockAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALEC Stock News HeadlinesSeptember 22, 2023 | benzinga.comAnalyst Expectations for Alector's FutureSeptember 15, 2023 | americanbankingnews.comAlector, Inc. (NASDAQ:ALEC) Major Shareholder Sells $3,000,000.00 in StockSeptember 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 9, 2023 | seekingalpha.comAlector completes enrollments in mid-stage Alzheimer’s trialSeptember 8, 2023 | msn.comAlector completes enrolment in AL002 trial to treat early Alzheimer’sAugust 31, 2023 | msn.comAlector (ALEC) Price Target Increased by 30.49% to 15.59August 12, 2023 | msn.comMizuho Maintains Alector (ALEC) Buy RecommendationAugust 10, 2023 | markets.businessinsider.comAlector (ALEC) Receives a Buy from Mizuho SecuritiesSeptember 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 9, 2023 | msn.comStifel Maintains Alector (ALEC) Hold RecommendationAugust 8, 2023 | msn.comMorgan Stanley Reiterates Alector (ALEC) Equal-Weight RecommendationAugust 5, 2023 | msn.comHC Wainwright & Co. Reiterates Alector (ALEC) Buy RecommendationAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)August 4, 2023 | marketwatch.comAlector Up 31% After 2Q Results, Drug Program UpdateJuly 27, 2023 | finance.yahoo.comAlector to Host Mid-Year Earnings Conference CallJuly 17, 2023 | msn.comAlector: Immuno-Neurology Innovator But Wait For The Pipeline SuccessJuly 7, 2023 | fool.comAlector (NASDAQ: ALEC)July 6, 2023 | msn.comAlector (ALEC) Price Target Increased by 6.49% to 11.95June 6, 2023 | finance.yahoo.comAlector to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceMay 18, 2023 | seekingalpha.comAlector (ALEC) Investor Presentation - SlideshowMay 5, 2023 | finance.yahoo.comBenign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share PriceMay 2, 2023 | finance.yahoo.comAlector to Participate in the BofA Securities 2023 Healthcare ConferenceApril 13, 2023 | finance.yahoo.comShareholders in Alector (NASDAQ:ALEC) are in the red if they invested three years agoFebruary 28, 2023 | finance.yahoo.comAlector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 17, 2023 | finance.yahoo.comAlector, Inc. (NASDAQ:ALEC) is a favorite amongst institutional investors who own 64%February 16, 2023 | finance.yahoo.comAlector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?January 28, 2023 | finance.yahoo.comAlector, Inc. (ALEC) Stock Historical Prices & Data - Yahoo FinanceSee More Headlines Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address ALEC Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees239Year Founded2013Price Target and Rating Average Stock Price Forecast$14.89 High Stock Price Forecast$41.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+122.9%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,310,000.00 Net Margins-140.18% Pretax Margin-136.51% Return on Equity-67.57% Return on Assets-18.57% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual Sales$133.62 million Price / Sales4.19 Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book2.58Miscellaneous Outstanding Shares83,830,000Free Float72,094,000Market Cap$559.98 million OptionableNot Optionable Beta0.75 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Arnon Rosenthal Ph.D. (Age 67)Co-Founder, CEO & Director Comp: $1.02MDr. Sara Kenkare-Mitra Ph.D. (Age 55)Pres and Head of R&D Comp: $1.19MDr. Marc Grasso M.D. (Age 50)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $738.05kDr. Gary Romano M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $602.98kMr. Peter Heutink Ph.D.Chief Scientific OfficerMs. Danielle Pasqualone J.D.Ph.D., Gen. CounselErica JeffersonVP of Communications & Public AffairsMichelle CorralVP of Communications & Investor RelationsMs. Clare Hunt M.B.A.Chief People OfficerMs. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerMore ExecutivesKey CompetitorsTarsus PharmaceuticalsNASDAQ:TARSHilleVaxNASDAQ:HLVXAnavex Life SciencesNASDAQ:AVXLExscientiaNASDAQ:EXAIAutolus TherapeuticsNASDAQ:AUTLView All CompetitorsInsiders & InstitutionsPolaris Venture Management Co.Sold 500,000 sharesTotal: $3 M ($6.00/share)Arnon RosenthalSold 5,647 sharesTotal: $29,307.93 ($5.19/share)Sara Kenkare-MitraSold 6,214 sharesTotal: $32,250.66 ($5.19/share)Marc GrassoSold 1,114 sharesTotal: $5,781.66 ($5.19/share)Virginia Retirement Systems ET ALBought 71,800 shares on 8/22/2023Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions ALEC Stock - Frequently Asked Questions Should I buy or sell Alector stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALEC shares. View ALEC analyst ratings or view top-rated stocks. What is Alector's stock price forecast for 2023? 8 Wall Street research analysts have issued 12-month target prices for Alector's stock. Their ALEC share price forecasts range from $8.00 to $41.00. On average, they expect the company's share price to reach $14.89 in the next year. This suggests a possible upside of 122.9% from the stock's current price. View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts. How have ALEC shares performed in 2023? Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 27.6% and is now trading at $6.68. View the best growth stocks for 2023 here. When is Alector's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ALEC earnings forecast. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) announced its quarterly earnings results on Thursday, August, 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.81) by $0.83. The business earned $56.21 million during the quarter, compared to the consensus estimate of $3.63 million. Alector had a negative net margin of 140.18% and a negative trailing twelve-month return on equity of 67.57%. What ETF holds Alector's stock ? iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio. What guidance has Alector issued on next quarter's earnings? Alector issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00 million-$100.00 million, compared to the consensus revenue estimate of $29.07 million. What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO). When did Alector IPO? (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. What is Alector's stock symbol? Alector trades on the NASDAQ under the ticker symbol "ALEC." Who are Alector's major shareholders? Alector's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.34%), Braidwell LP (4.93%), State Street Corp (3.24%), JPMorgan Chase & Co. (2.86%), Point72 Asset Management L.P. (2.07%) and Franklin Resources Inc. (1.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alector's stock price today? One share of ALEC stock can currently be purchased for approximately $6.68. How much money does Alector make? Alector (NASDAQ:ALEC) has a market capitalization of $559.98 million and generates $133.62 million in revenue each year. The company earns $-133,310,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. How many employees does Alector have? The company employs 239 workers across the globe. Does Alector have any subsidiaries? The following companies are subsidiares of Alector: Alector LLC.Read More How can I contact Alector? Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com. This page (NASDAQ:ALEC) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.